Long-term follow-up: No effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2343-2347

  Lindenburg, Catharina E A ^a   Stolte, Ineke ^a   Langendam, Miranda W ^a   Miedema, Frank ^b,c   Williams, Ian G ^d   Colebunders, Robert ^e   Weber, Jonathan N ^f   Fisher, Martin ^g   Coutinho, Roel A ^a,c  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f ST MARY S HOSPITAL   (United Kingdom)

^g ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

HIV 1 p17 p24:Ty virus like particles; Long term effects; Therapeutic vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL COUNT; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LINEAR REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION; VIRUS PARTICLE;

EID: 0037157242     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00102-0     Document Type: Article

References (27)

1. Prospects for the control of AIDS by immunizing seropositive individuals
2. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses
3. The expression of hybrid HIV:Ty virus-like particles in yeast
4. HIV p24-specific helper T-cell clones from immunized primates recognize highly conserved regions of HIV-1
5. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers
6. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons
7. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV-seropositive subjects
8. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators
9. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals
10. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T-lymphocyte activity in asymptomatic HIV-infected individuals
11. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections
12. Expanded European AIDS case definition
13. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research
14. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: Evaluation of the T-cell proliferative response
15. Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: Relationship to cellular immune responses
16. Phase II controlled trial of post-exposure immunization with recombinant gp 160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults
17. 3. AIDS Clinical Trials Group Protocol 137
18. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160
19. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: Results of a double-blind, adjuvant-controlled trial
20. Two double-blinded, randomized, comparative trials of four human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity. AIDS Clinical Trials Groups 209 and 214
21. + cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine
22. Recombinant gp160 as a therapeutic vaccine for HIV-infection: Results of a large randomized
23. Randomized trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection
24. Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency
25. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators
26. Therapeutic immunization with recombinant gp160 in HIV-1 infection: A randomized double-blind placebo-controlled trial. Nordic VAC-04 Study Group
27. The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population